KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Accured Expenses (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Change in Accured Expenses for 16 consecutive years, with $425000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 199.3% year-over-year to $425000.0, compared with a TTM value of -$182000.0 through Sep 2025, up 95.57%, and an annual FY2024 reading of -$1.0 million, up 93.6% over the prior year.
  • Change in Accured Expenses was $425000.0 for Q3 2025 at TherapeuticsMD, up from -$190000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $19.1 million in Q3 2022 and bottomed at -$14.1 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is -$384684.2, with a median of -$190000.0 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses skyrocketed 3282.27% in 2022, then tumbled 331.82% in 2025.
  • Year by year, Change in Accured Expenses stood at -$8.9 million in 2021, then tumbled by 58.77% to -$14.1 million in 2022, then soared by 73.04% to -$3.8 million in 2023, then soared by 81.79% to -$691000.0 in 2024, then surged by 161.51% to $425000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for TXMD at $425000.0 in Q3 2025, -$190000.0 in Q2 2025, and $274000.0 in Q1 2025.